Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
Vivani Medical (NASDAQ: VANI), a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants, has announced its participation in the upcoming Emerging Growth Conference on March 27, 2025.
Company President and CEO Adam Mendelsohn, Ph.D. will deliver a 30-minute presentation starting at 2:20 pm Eastern Time. The interactive session will include a company overview and a potential Q&A segment, providing individual and institutional investors, advisors, and analysts the opportunity to engage directly with management.
Investors can submit questions in advance to Questions@EmergingGrowth.com. The presentation will be archived and available on EmergingGrowth.com and the Emerging Growth YouTube channel post-conference.
Vivani Medical (NASDAQ: VANI), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di impianti per farmaci miniaturizzati e a lunga durata, ha annunciato la sua partecipazione alla prossima Emerging Growth Conference che si terrà il 27 marzo 2025.
Il Presidente e CEO dell'azienda, Adam Mendelsohn, Ph.D., presenterà un intervento di 30 minuti che inizierà alle 14:20 ora orientale. La sessione interattiva includerà una panoramica dell'azienda e un possibile segmento di domande e risposte, offrendo a investitori individuali e istituzionali, consulenti e analisti l'opportunità di interagire direttamente con la direzione.
Gli investitori possono inviare domande in anticipo a Questions@EmergingGrowth.com. La presentazione sarà archiviata e disponibile su EmergingGrowth.com e sul canale YouTube di Emerging Growth dopo la conferenza.
Vivani Medical (NASDAQ: VANI), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de implantes de medicamentos miniaturizados y de acción prolongada, ha anunciado su participación en la próxima Emerging Growth Conference que se llevará a cabo el 27 de marzo de 2025.
El Presidente y CEO de la compañía, Adam Mendelsohn, Ph.D., ofrecerá una presentación de 30 minutos que comenzará a las 2:20 p.m. hora del Este. La sesión interactiva incluirá una visión general de la empresa y un posible segmento de preguntas y respuestas, brindando a inversores individuales e institucionales, asesores y analistas la oportunidad de interactuar directamente con la dirección.
Los inversores pueden enviar preguntas por adelantado a Questions@EmergingGrowth.com. La presentación se archivará y estará disponible en EmergingGrowth.com y en el canal de YouTube de Emerging Growth después de la conferencia.
비바니 메디컬 (NASDAQ: VANI)는 미니어처 초장기 약물 이식물 개발에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 3월 27일에 열리는 신흥 성장 컨퍼런스에 참여한다고 발표했습니다.
회사의 사장 겸 CEO인 아담 멘델소hn, Ph.D.는 동부 표준시 기준으로 오후 2시 20분에 시작되는 30분 발표를 진행할 예정입니다. 이 인터랙티브 세션에는 회사 개요와 잠재적인 Q&A 세션이 포함되어 있으며, 개인 및 기관 투자자, 자문가 및 분석가들이 경영진과 직접 소통할 수 있는 기회를 제공합니다.
투자자들은 미리 Questions@EmergingGrowth.com으로 질문을 제출할 수 있습니다. 발표는 보관되어 컨퍼런스 후 EmergingGrowth.com과 Emerging Growth 유튜브 채널에서 이용할 수 있습니다.
Vivani Medical (NASDAQ: VANI), une entreprise biopharmaceutique en phase clinique axée sur le développement d'implants médicamenteux miniatures à action ultra prolongée, a annoncé sa participation à la prochaine Emerging Growth Conference qui se tiendra le 27 mars 2025.
Le Président et PDG de l'entreprise, Adam Mendelsohn, Ph.D., présentera une intervention de 30 minutes qui débutera à 14h20, heure de l'Est. La session interactive comprendra une vue d'ensemble de l'entreprise et un segment potentiel de questions-réponses, offrant aux investisseurs individuels et institutionnels, aux conseillers et aux analystes l'opportunité d'interagir directement avec la direction.
Les investisseurs peuvent soumettre des questions à l'avance à Questions@EmergingGrowth.com. La présentation sera archivée et disponible sur EmergingGrowth.com et sur la chaîne YouTube d'Emerging Growth après la conférence.
Vivani Medical (NASDAQ: VANI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von miniaturisierten, ultra-langwirksamen Arzneimittelimplantaten konzentriert, hat seine Teilnahme an der bevorstehenden Emerging Growth Conference am 27. März 2025 angekündigt.
Der Präsident und CEO des Unternehmens, Adam Mendelsohn, Ph.D., wird eine 30-minütige Präsentation halten, die um 14:20 Uhr Eastern Time beginnt. Die interaktive Sitzung wird eine Unternehmensübersicht und einen möglichen Q&A-Abschnitt umfassen, der Einzel- und institutionellen Investoren, Beratern und Analysten die Möglichkeit bietet, direkt mit dem Management in Kontakt zu treten.
Investoren können im Voraus Fragen an Questions@EmergingGrowth.com senden. Die Präsentation wird archiviert und nach der Konferenz auf EmergingGrowth.com und dem YouTube-Kanal von Emerging Growth verfügbar sein.
- None.
- None.
Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investment community the opportunity to engage directly with Vivani President and CEO Adam Mendelsohn, Ph.D. Dr. Mendelsohn will provide an overview of the Company and, time permitting, open the floor to questions afterward. Please submit your questions in advance to: Questions@EmergingGrowth.com.
Vivani will be presenting for 30 minutes starting at 2:20 pm Eastern Time.
Please register at the following link to attend the conference and receive any updates released in follow up to the Vivani presentation: https://emerginggrowth.com/emerging-growth-conference-80/.
An archived webcast will be made available after the conference on EmergingGrowth.com and on the Emerging Growth YouTube channel, http://www.YouTube.com/EmergingGrowthConference.
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Vivani’s emerging pipeline includes NPM-139 (semaglutide implant) which is also under development for chronic weight management in obese and overweight individuals. The semaglutide implant has the added potential benefit of once-yearly administration. NPM-119 refers to the Company’s six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 trial and reporting of trial results, Vivani’s emerging development plans for NPM-115, NPM-139, NPM-119, or Vivani’s plans with respect to Cortigent and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani’s products, including NPM-115, NPM-139, and NPM-119; delays and changes in the development of Vivani’s products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani’s development activities; risks related to the initiation, enrollment and conduct of Vivani’s planned clinical trials and the results therefrom; Vivani’s history of losses and Vivani’s ability to access additional capital or otherwise fund Vivani’s business; market conditions and the ability of Cortigent to complete its intended spin-off from the Company. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324242867/en/
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
investors@vivani.com
(415) 506-8462
Media Contact:
Sean Leous
ICR Healthcare
Sean.Leous@ICRHealthcare.com
(646) 866-4012
Source: Vivani Medical, Inc.